You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 46 No. 8, August 1989 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (231)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Cholinergic Hyperactivity and Negative Schizophrenic Symptoms

A Model of Cholinergic/Dopaminergic Interactions in Schizophrenia

Rajiv Tandon, MD; John F. Greden, MD

Arch Gen Psychiatry. 1989;46(8):745-753.


Abstract



• Despite renewed interest in negative schizophrenic symptoms, the pathophysiological mechanisms involved in their development remain obscure. Although the cholinergic system has been implicated in schizophrenia, it has not been accorded a major role in current theories of pathophysiology. We present evidence from several lines of research that suggests that muscarinic hyperactivity may be implicated in the pathogenesis of negative schizophrenic symptoms. Specifically, cholinergic overdrive leads to a behavioral syndrome strikingly similar to the negative schizophrenic syndrome, anticholinergic agents may alleviate negative symptoms, schizophrenic patients with negative symptoms tend to "abuse" anticholinergics, and polysomnographic, neuroendocrine, and other pharmacological findings appear to be generally consistent with this hypothesis. The hypothesis is testable and is presented as a heuristic model that focuses on the dynamic interplay between cholinergic and dopaminergic systems in schizophrenia.



Author Affiliations



From the Schizophrenia Program, Department of Psychiatry, University of Michigan Medical Center, Ann Arbor.


Footnotes



Accepted for publication December 12, 1988.

Reprint requests to Schizophrenia Program, UH-9C-9150, University of Michigan Medical Center, Ann Arbor, MI 48109-0120 (Dr Tandon).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia
Sarter et al.
Schizophr Bull 2005;31:117-138.
ABSTRACT | FULL TEXT  

Antibodies Against Cerebral M1 Cholinergic Muscarinic Receptor from Schizophrenic Patients: Molecular Interaction
Borda et al.
J. Immunol. 2002;168:3667-3674.
ABSTRACT | FULL TEXT  

Acute psychosis after CPAP treatment in a schizophrenic patient with sleep apnoea{-}hypopnoea syndrome
Chiner et al.
Eur Respir J 2001;17:313-315.
ABSTRACT | FULL TEXT  

Effects of chewing betel nut (Areca catechu) on the symptoms of people with schizophrenia in Palau, Micronesia
SULLIVAN et al.
Br. J. Psychiatry 2000;177:174-178.
ABSTRACT | FULL TEXT  

Muscarinic Receptor Agonists, Like Dopamine Receptor Antagonist Antipsychotics, Inhibit Conditioned Avoidance Response in Rats
Shannon et al.
J. Pharmacol. Exp. Ther. 1999;290:901-907.
ABSTRACT | FULL TEXT  

Dopamine Modulates the Responsivity of Mediodorsal Thalamic Cells Recorded In Vitro
Lavin and Grace
J. Neurosci. 1998;18:10566-10578.
ABSTRACT | FULL TEXT  

Glutamate Receptor Dysfunction and Schizophrenia
Olney and Farber
Arch Gen Psychiatry 1995;52:998-1007.
ABSTRACT  

Symptoms of Schizophrenia: Methods, Meanings, and Mechanisms
Andreasen et al.
Arch Gen Psychiatry 1995;52:341-351.
ABSTRACT  

Book Reviews : The cognitive neuropsychology of schizophrenia: opening black boxes and creating new ones: The Neuropsychology of Schizophrenia (eds Anthony S. David and John C. Cutting), Lawrence Erlbaum Associates, Hove, UK, 1994. ISBN 0-86377-303-6. The Cognitive Neuropsychology of Schizophrenia (Christopher D. Frith), Lawrence Erlbaum Associates, Hove, UK, 1993. ISBN 0-86377-224-2
Sarter and Smith
J Psychopharmacol 1995;9:290-291.
 

Muscarinic Effects of Clozapine and Negative Symptoms
Keshavan
Arch Gen Psychiatry 1993;50:835-835.
ABSTRACT  

Neuropharmacologic Basis for Clozapine's Unique Profile
Tandon and Kane
Arch Gen Psychiatry 1993;50:158-159.
ABSTRACT  

Psychotic Symptoms Preceding Ocular Deviation in a Patient with Tardive Oculogyric Crises
Sachdev and Tang
Aust N Z J Psychiatry 1992;26:666-670.
ABSTRACT  

Electroencephalographic Sleep Abnormalities in Schizophrenia: Relationship to Positive/Negative Symptoms and Prior Neuroleptic Treatment
Tandon et al.
Arch Gen Psychiatry 1992;49:185-194.
ABSTRACT  

The Positive-Negative Distinction in Schizophrenia: Review of Natural History Validators
McGlashan and Fenton
Arch Gen Psychiatry 1992;49:63-72.
ABSTRACT  

Reciprocal Changes in Psychosis and Mood After Physostigmine in a Patient With Alzheimer's Disease
Molchan et al.
Arch Gen Psychiatry 1991;48:1113-1114.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.